[go: up one dir, main page]

SG11202104721RA - Delivery constructs for transcytosis and related methods - Google Patents

Delivery constructs for transcytosis and related methods

Info

Publication number
SG11202104721RA
SG11202104721RA SG11202104721RA SG11202104721RA SG11202104721RA SG 11202104721R A SG11202104721R A SG 11202104721RA SG 11202104721R A SG11202104721R A SG 11202104721RA SG 11202104721R A SG11202104721R A SG 11202104721RA SG 11202104721R A SG11202104721R A SG 11202104721RA
Authority
SG
Singapore
Prior art keywords
transcytosis
related methods
delivery constructs
constructs
delivery
Prior art date
Application number
SG11202104721RA
Other languages
English (en)
Inventor
Amir Porat
Elbert Seto
Charles Olson
Randall J Mrsny
Tahir Mahmood
Weijun Feng
Sally Postlethwaite
Original Assignee
Applied Molecular Transport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/021474 external-priority patent/WO2019173787A1/fr
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/fr
Application filed by Applied Molecular Transport Inc filed Critical Applied Molecular Transport Inc
Publication of SG11202104721RA publication Critical patent/SG11202104721RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202104721RA 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods SG11202104721RA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
PCT/US2019/021474 WO2019173787A1 (fr) 2018-03-08 2019-03-08 Constructions d'administration dérivées de toxines pour administration orale
US201962888133P 2019-08-16 2019-08-16
US201962888238P 2019-08-16 2019-08-16
PCT/US2019/050708 WO2020096695A1 (fr) 2018-11-07 2019-09-11 Supports dérivés de cholix pour administration orale de chargement hétérologue
PCT/US2019/060356 WO2020097394A1 (fr) 2018-11-07 2019-11-07 Constructions d'administration pour la transcytose et méthodes associées

Publications (1)

Publication Number Publication Date
SG11202104721RA true SG11202104721RA (en) 2021-06-29

Family

ID=70612266

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104721RA SG11202104721RA (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods

Country Status (21)

Country Link
US (3) US11027020B2 (fr)
EP (2) EP4083058A3 (fr)
JP (2) JP7516369B2 (fr)
KR (1) KR20210110294A (fr)
CN (1) CN113423722A (fr)
AU (1) AU2019377117B2 (fr)
BR (1) BR112021009003A2 (fr)
CA (1) CA3119060A1 (fr)
CL (1) CL2021001209A1 (fr)
CO (1) CO2021007402A2 (fr)
CY (1) CY1125216T1 (fr)
DK (1) DK3650037T3 (fr)
EA (1) EA202191280A1 (fr)
ES (1) ES2911075T3 (fr)
IL (1) IL282987B2 (fr)
MX (1) MX2021005346A (fr)
PL (1) PL3650037T3 (fr)
PT (1) PT3650037T (fr)
SG (1) SG11202104721RA (fr)
TW (1) TW202031678A (fr)
WO (1) WO2020097394A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
SI3762009T1 (sl) 2018-03-08 2023-03-31 Applied Molecular Transport Inc. Iz toksinov izpeljani dostavni konstrukti za peroralno dostavo
PL3650037T3 (pl) 2018-11-07 2022-06-06 Applied Molecular Transport Inc. Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby
WO2020096695A1 (fr) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Supports dérivés de cholix pour administration orale de chargement hétérologue
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
AU2021286574A1 (en) * 2020-06-09 2023-01-19 Icosavax, Inc. Method of making virus-like particle
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0188256B1 (fr) 1985-01-14 1991-08-21 NeoRx Protéines marquées par un radionuclide d'un métal pour diagnostic et thérapie
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP2014298A3 (fr) * 2000-08-24 2009-10-07 Genentech, Inc. Polypeptides d'interleukine-22, acides nucléiques les codant et procédés de traitement des troubles pancréatiques
IL156041A0 (en) 2000-11-27 2003-12-23 Powderject Vaccines Inc Nucleic acid adjuvants
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
JP4339598B2 (ja) 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
CA2530386A1 (fr) * 2003-06-23 2005-01-06 Jing Li Anticorps contre l'interleukine-22 et utilisations
EP1522585A1 (fr) 2003-10-09 2005-04-13 Plant Research International B.V. Molécules porteuses chimères pour la production de vaccins absorbés au niveau des muqueuses
US20090155297A1 (en) 2004-10-04 2009-06-18 Trinity Biosystems, Inc. Methods and Compositions for Inducing an Immune Response Against Multiple Antigens
JP2008515808A (ja) 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
US20070148131A1 (en) 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
JP2010500967A (ja) * 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
EP2079450A2 (fr) 2006-11-08 2009-07-22 Novavax, INC. Procédé pour préparer des formes de dosage solides de compositions pharmaceutiques à plusieurs phases
US8524241B2 (en) * 2007-07-20 2013-09-03 The General Hospital Corporation Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US20110250199A1 (en) 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
KR20190064664A (ko) 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
EP3366692A1 (fr) * 2009-06-22 2018-08-29 Amgen, Inc Repliement de protéines au moyen d' un état redox chimiquement régulé
EP2456470A1 (fr) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Système d'administration et conjugués pour l'administration de composés par des voies de transport intracellulaire naturelles
WO2011031441A1 (fr) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Thérapie avec une molécule chimérique et un agent pro-apoptotique
NO2616045T3 (fr) 2010-09-15 2018-03-24
EP2667898A1 (fr) 2011-01-26 2013-12-04 Cenix Bioscience GmbH Système d'administration et conjugués pour l'administration de composés par des voies de transport intracellulaire naturelles
DK2726091T3 (da) 2011-06-29 2020-03-09 Rani Therapeutics Llc Præparater med terapeutisk middel til fremføring i et lumen i tarmkanalen ved hjælp af en synkbar anordning til lægemiddelfremføring
KR102426481B1 (ko) * 2013-03-15 2022-07-27 제넨테크, 인크. IL-22 폴리펩티드 및 IL-22 Fc 융합 단백질 및 사용 방법
US20160287670A1 (en) 2013-11-07 2016-10-06 Memorial Sloan-Kettering Cancer Center Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3998077A1 (fr) 2014-05-07 2022-05-18 Applied Molecular Transport Inc. Molécules de fusion dérivées de la toxine cholix pour l'administration par voie orale d'une charge biologiquement active
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20170362291A1 (en) * 2014-12-23 2017-12-21 Armo Biosciences, Inc. Methods of Improving Yield in Recombinant Protein Production
EP3192805A1 (fr) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibiteurs de l'activation ou la stimulation des lymphocytes t et leurs utilisations
AU2017291321B2 (en) 2016-06-22 2020-06-18 Alkermes, Inc. Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
WO2018112264A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du récepteur de chimiokine
EP3554346B1 (fr) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunosuppresseur
PT3762009T (pt) * 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
PL3650037T3 (pl) 2018-11-07 2022-06-06 Applied Molecular Transport Inc. Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby
US20200140511A1 (en) 2018-11-07 2020-05-07 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
WO2020096695A1 (fr) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Supports dérivés de cholix pour administration orale de chargement hétérologue

Also Published As

Publication number Publication date
IL282987B2 (en) 2023-02-01
EP3650037B1 (fr) 2022-03-02
CN113423722A (zh) 2021-09-21
IL282987A (en) 2021-06-30
TW202031678A (zh) 2020-09-01
AU2019377117B2 (en) 2025-05-29
EA202191280A1 (ru) 2021-12-27
AU2019377117A1 (en) 2021-06-10
EP4083058A3 (fr) 2023-01-11
CL2021001209A1 (es) 2021-11-19
US20210338828A1 (en) 2021-11-04
JP7516369B2 (ja) 2024-07-16
JP2024127939A (ja) 2024-09-20
IL282987B (en) 2022-10-01
PL3650037T3 (pl) 2022-06-06
MX2021005346A (es) 2021-10-13
CO2021007402A2 (es) 2021-09-30
WO2020097394A1 (fr) 2020-05-14
CA3119060A1 (fr) 2020-05-14
DK3650037T3 (da) 2022-05-02
CY1125216T1 (el) 2024-12-13
PT3650037T (pt) 2022-06-27
EP4083058A2 (fr) 2022-11-02
JP2022506990A (ja) 2022-01-17
KR20210110294A (ko) 2021-09-07
US20200306383A1 (en) 2020-10-01
EP3650037A1 (fr) 2020-05-13
BR112021009003A2 (pt) 2021-08-17
US20240238429A1 (en) 2024-07-18
ES2911075T3 (es) 2022-05-17
US11027020B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
IL282987B (en) Delivery constructs for transcytosis and related methods
IL276464A (en) Methods and preparations for administering therapeutic protein
IL276715A (en) Preparations and methods for administration of membrane protein
ZA202105676B (en) Anti-trem2 antibodies and related methods
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL278061A (en) Structures of antibodies against ROR
SG10202000793XA (en) Antibody constructs for flt3 and cd3
PT3762009T (pt) Construções de administração derivadas de toxinas para administração oral
IL282369A (en) Preparations and methods for administering transgenes
IL278490A (en) Proteins with both taste and smell
IL265831A (en) Preparations and methods for protein expression and administration
IL292259A (en) flt3-targeted antibodies and their uses
IL290279A (en) Implantable structures and their use
IL282708A (en) Anti-tim-3 antibodies and their use
ZA201907063B (en) Insecticidal proteins and methods for their use
IL282707A (en) Anti-tim-3 antibodies and their use
IL277209A (en) Structures for administration of toxin derivatives for oral administration
ZA202210284B (en) Anti-trem1 antibodies and related methods
GB2561563B (en) Fuel delivery apparatus and method
HK40108701A (en) Antibody constructs for msln and cd3
HK40099430A (en) Delivery devices and methods for making the same
GB2582542B (en) Connector and associated methods
HK40042312A (en) Methods and compositions for therapeutic protein delivery
HK40019044A (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
HK1233279A1 (en) Chimeric antigen receptors (car) for use in therapy and methods for making the same